Vivos Therapeutics (VVOS) Stock Forecast & Price Target

Vivos Therapeutics is facing some challenges in the short term, such as a net loss in Q4 FY25 due to the transition to a new distribution strategy and consolidating operations. However, the company's revenue is growing, driven by increasing demand for sleep testing services and treatment for obstructive sleep apnea. The Vivos System also appears to be a promising alternative to the current standard of care for OSA and could become the preferred treatment option in the future. While additional capital investments may be needed, the company's potential for revenue growth and operational efficiency make it a promising investment with a price target of $2.50.

Vivos Therapeutics is facing some challenges such as low visibility on revenues and margins, risks related to regulatory approvals, and the need for more financing in the near future. While the company has seen an increase in gross margins and is continuing to expand its channel and offering, there is still uncertainty surrounding its future profitability. Additionally, there is potential dilution from future financing rounds to consider, which may negatively impact shareholder value.